$XENE Xenon Pharmaceuticals Inc. Insider Trading Week 38/2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Xenon Pharmaceuticals Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Xenon Pharmaceuticals Inc. in week 38/2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 2.68 | 785 | 2,104 | 243 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 2.68 | 7,973 | 21,368 | 4,372 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 3.73 | 3,115 | 11,619 | 1,000 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 3.52 | 3,703 | 13,035 | 0 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 3.56 | 6,172 | 21,972 | 0 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 3.07 | 5,144 | 15,792 | 0 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 3.77 | 1,028 | 3,876 | 0 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 3.21 | 2,057 | 6,603 | 0 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Option Exercise | M | 5.22 | 411 | 2,145 | 0 | |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Sell | S | 8.60 | 12,000 | 103,200 | 6,000 | 18 K to 6 K (-66.67 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Sell | S | 9.02 | 4,000 | 36,080 | 18,000 | 22 K to 18 K (-18.18 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Sell | S | 9.33 | 6,149 | 57,384 | 22,000 | 28.1 K to 22 K (-21.84 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 167 | 1,592 | 28,149 | 28.3 K to 28.1 K (-0.59 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 2.68 | 785 | 2,104 | 28,316 | 27.5 K to 28.3 K (+2.85 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 1,687 | 16,077 | 27,531 | 29.2 K to 27.5 K (-5.77 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 2.68 | 7,973 | 21,368 | 29,218 | 21.2 K to 29.2 K (+37.53 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 923 | 8,796 | 21,245 | 22.2 K to 21.2 K (-4.16 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 3.73 | 3,115 | 11,619 | 22,168 | 19.1 K to 22.2 K (+16.35 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 1,098 | 10,464 | 19,053 | 20.2 K to 19.1 K (-5.45 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 3.52 | 3,703 | 13,035 | 20,151 | 16.4 K to 20.2 K (+22.51 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 1,829 | 17,430 | 16,448 | 18.3 K to 16.4 K (-10.01 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 3.56 | 6,172 | 21,972 | 18,277 | 12.1 K to 18.3 K (+50.99 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 1,525 | 14,533 | 12,105 | 13.6 K to 12.1 K (-11.19 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 3.07 | 5,144 | 15,792 | 13,630 | 8.5 K to 13.6 K (+60.62 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 305 | 2,907 | 8,486 | 8.8 K to 8.5 K (-3.47 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 3.77 | 1,028 | 3,876 | 8,791 | 7.8 K to 8.8 K (+13.24 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 610 | 5,813 | 7,763 | 8.4 K to 7.8 K (-7.29 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 3.21 | 2,057 | 6,603 | 8,373 | 6.3 K to 8.4 K (+32.57 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Payment of Exercise | F | 9.53 | 198 | 1,887 | 6,316 | 6.5 K to 6.3 K (-3.04 %) |
| Sep 24 2015 | XENE | Xenon Pharmaceutic ... | GOLDBERG Y. PAUL | VP of Clinical Deve ... | Buy | M | 5.22 | 411 | 2,145 | 6,514 | 6.1 K to 6.5 K (+6.73 %) |